首页> 外文OA文献 >Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration
【2h】

Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration

机译:病毒性肝炎疫苗:将皮内和皮下与肌肉内给药进行比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BACKGROUND: Vaccination against hepatitis A virus (HAV) is unaffordable to many developing countries. Substantial reductions in cost occur when vaccines are administered intradermally at low doses. Aluminum-free HAV vaccines are considered more suitable for intradermal use than traditional vaccines which can cause long-lasting local reactions. Thus, we compared the immunogenicity and safety of an aluminum-free virosomal HAV vaccine (Epaxal) administered by different routes: intradermal (i.d.), subcutaneous (s.c.), and intramuscular (i.m.). METHODS: Two open pilot studies were conducted as sub-studies of a large lot consistency trial. Healthy subjects aged 18 to 45 were enrolled. Study 1 compared two i.d. regimens of a lower dose of Epaxal [0.1 mL (4.8 IU), one or two injection sites] with i.m. administration of the standard dose [0.5 mL (24 IU)]. Study 2 compared the s.c. with the i.m. administration of the standard dose. At month 12, subjects in study 1 received a booster dose of 0.1 mL i.d. or 0.5 mL i.m.; subjects in study 2 received 0.5 mL via the respective route (s.c. or i.m.). Serum was tested for antibodies at baseline, 2 weeks (study 1), and 1 and 6 months after the primary vaccination as well as prior and 1 month after the booster dose. Incidences of solicited and unsolicited adverse events were recorded. RESULTS: Seroprotection rates (anti-HAV geometric mean concentration of > or =20 mIU/mL) after 1 month ranged from 93.2% to 100% in all groups and remained high until month 12 (range 85.2&-90.2%). Complete (100%) seroprotection was achieved by all subjects in all groups after booster vaccination. All routes of administration were well tolerated. Local reactions were more common in subjects vaccinated i.d. and s.c. than i.m. CONCLUSIONS: The aluminum-free virosomal HAV vaccine Epaxal is highly immunogenic and well tolerated when administered either via i.d., s.c., or i.m. Vaccination via the i.d. route may confer significant cost savings over the conventional i.m. route.
机译:背景:许多发展中国家买不起针对甲型肝炎病毒(HAV)的疫苗。当以低剂量皮内注射疫苗时,可大大降低成本。与传统疫苗相比,无铝HAV疫苗被认为更适合皮内使用,因为传统疫苗会引起长期的局部反应。因此,我们比较了通过不同途径施用的无铝病毒性HAV疫苗(Epaxal)的免疫原性和安全性:皮内(i.d.),皮下(s.c.)和肌内(i.m.)。方法:进行了两个开放式试验研究,作为大批量一致性试验的子研究。纳入年龄在18至45岁之间的健康受试者。研究1比较了两个i.d. i.m.使用较低剂量的Epaxal [0.1 mL(4.8 IU),一个或两个注射部位]的方案。服用标准剂量[0.5 mL(24 IU)]。研究2比较了s.c.与我服用标准剂量。在第12个月,研究1的受试者在当日接受0.1 mL的加强剂量。或0.5 mL i.m .;研究2中的受试者分别通过皮下注射(s.c.或i.m.)接受了0.5毫升。在基线,初次疫苗接种后2周(研究1),加强免疫后1个月和6个月以及加强剂量之前和之后1个月对血清进行抗体测试。记录主动和主动的不良事件的发生率。结果:所有组在1个月后的血清保护率(抗HAV几何平均浓度>或= 20 mIU / mL)在所有组中从93.2%到100%不等,直到12个月仍然很高(范围85.2&-90.2%)。加强免疫后所有组的所有受试者均达到了完全(100%)的血清保护。所有给药途径均耐受良好。局部反应在接种疫苗的受试者中更为普遍。和s.c.比我结论:无铝的病毒性HAV疫苗Epaxal具有高度免疫原性,并且在经腹膜内或皮下注射后均可耐受。通过i.d.接种疫苗与传统的i.m相比,这种路线可以节省大量成本。路线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号